News
Eli Lilly Prepares to Report Q3 Earnings Focused on Weight-Loss Drugs
Eli Lilly is scheduled to report its third-quarter financial results before the market opens on October 29. Wall Street consensus estimates project total revenue of approximately $22.6 billion, representing a 28% year-over-year increase. Non-GAAP adjusted earnings per share are expected to range between $5.70 and $6.70. A primary focus for the report is the performance of blockbuster drugs Mounjaro and Zepbound, which are projected to generate around $10 billion and $5 billion respectively. Investors will also monitor sales of the oral weight-loss drug Foundayo and potential revisions to full-year guidance.